In a “tale of two trials,” Drs. Ogbeide and Osarogiagbon use insights from the ALCHEMIST trial population to try to understand outcomes disparities between North America and Japan. Read more
During ACLC 2022, Dr. Noemi Reguart reviewed the data for MET-targeting TKIs and monoclonal antibodies for patients with METex14 skipping mutations, MET amplification, and MET overexpression. Read more
Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration
+more
Beyond sotorasib, dozens of small molecule inhibitors are being explored to target this oncogenic driver. Get up to date as researchers from Roswell Park Comprehensive Cancer Center summarize the KRAS trial landscape. Read more
Drs. Stephanie Saw and Daniel Tan stress the importance of understanding the intricacies of HER2 testing in non-small cell lung cancer to optimize patient selection. Read more
During a lecture at NACLC 22, Dr. Christian Rolfo illustrated how ctDNA could be used to monitor progression and inform treatment decisions. Read more
Using a real-world cohort of US veterans, researchers examine the effectiveness of durvalumab consolidation in unresectable stage III NSCLC. Read more
During IASLC’s North America Conference on Lung Cancer, MD Anderson’s Dr. Tina Cascone reviewed the evidence for neoadjuvant and adjuvant therapy in NSCLC. Read more
Grouping mutations based on their likelihood of response to specific drug types in future EGFR TKI trials may eventually help physicians tailor treatments for patients with atypical mutations. Read more
Investigators at Sarah Cannon look to next-generation sequencing for molecular signatures that may correlate with response. Read more
Researchers say increased screening of at-risk populations, including those who have never smoked, may improve survival more than any other strategy. Read more